Towards novel antifilarial drugs: Challenges and recent developments

Future Medicinal Chemistry

Volumn 2, Issue 2, 2010, Pages 251-283

  Singh, Prashant Kumar ^a   Ajay, Arya ^a   Kushwaha, Susheela ^a   Tripathi, Rama Pati ^a   Misra Bhattacharya, Shailja ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ANTHRAQUINONE DERIVATIVE; ANTIFILARIAL AGENT; AZITHROMYCIN; BENZIMIDAZOLE DERIVATIVE; CHLORAMBUCIL; CLOSANTEL; COUMARIN DERIVATIVE; DIETHYL CARBAMAZINE; DOXYCYCLINE; IVERMECTIN; LEVAMISOLE; MOXIDECTIN; NEOEUDISTOMIN DERIVATIVE; NICLOSAMIDE; NITAZOXANIDE; ORGANOMETALLIC COMPOUND; PHENOTHIAZINE DERIVATIVE; POLYCARPOL; PYRIMIDINE DERIVATIVE; QUINOLONE DERIVATIVE; RIFAMPICIN; SURAMIN; THIOCYANATIN D; THIOCYANATIN D1; THIOCYANATIN D2; THIOCYANATIN E1; TIZOXANIDE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BRUGIA MALAYI; BRUGIA TIMORI; CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; FILARIA; FILARIASIS; GENOMICS; HUMAN; LOA LOA; LYMPHATIC FILARIASIS; MANSONELLA OZZARDI; MANSONELLA PERSTANS; MANSONELLA STREPTOCERCA; NONHUMAN; ONCHOCERCA VOLVULUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TROPICAL DISEASE; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY; WUCHERERIA BANCROFTI;

ANIMALS; FILARIASIS; FILARICIDES; FILARIOIDEA; HOST-PARASITE INTERACTIONS; HUMANS;

EID: 77953471201     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.170     Document Type: Review

References (280)

1. Palumbo E. Filariasis: diagnosis, treatment and prevention. Acta Biomed. 79(2), 106-109 (2008).
2. Evans DB, Gelband H, Vlassoff C. Social and economic factors and the control of lymphatic filariasis: a review. Acta Trop. 53(1), 1-26 (1993).
3. Gyapong JO, Gyapong M, Evans DB, Aikins MK, Adjei S. The economic burden of lymphatic filariasis in northern Ghana. Ann. Trop. Med. Parasitol. 90(1), 39-48 (1996).
4. Ramaiah KD, Radhamani MP, John KR et al. The impact of lymphatic filariasis on labour inputs in southern India: results of a multi-site study. Ann. Trop. Med. Parasitol. 94(4), 353-364 (2000).
5. Haddix AC, Kestler A. Lymphatic filariasis: economic aspects of the disease and programmes for its elimination. Trans. R. Soc. Trop. Med. Hyg. 94(6), 592-593 (2000).
6. Molyneux DH, Taylor MJ. Current status and future prospects of the Global Lymphatic Filariasis Programme. Curr. Opin. Infect. Dis. 14(2), 155-159 (2001).
7. Behbehani K. Candidate parasitic diseases. Bull. World Health Organ. 76(2), 64-67 (1998).
8. World Health Organization. Elimination of lymphatic filariasis as a public health problem. Presented at: World Health Assembly. Geneva, Switzerland May 13 1997.
9. Molyneux DH. Onchocerciasis control and elimination: coming of age in resource-constrained health systems. Trends Parasitol. 21(11), 525-529 (2005).
10. Molyneux DH. Filaria control and elimination: diagnostic, monitoring and surveillance needs. Trans. R. Soc. Trop. Med. Hyg. 103(4), 338-341 (2009).
11. Remme JHF. The African programme for onchocerciasis control: preparing for launch. Parasitol. Today 11(11), 399-402 (1995).
12. Ottesen EA, Hooper PJ, Bradley M, Biswas G. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl. Trop. Dis. 2(10), E317 (2008).
13. Atweneboana MYO, Eng JKL, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 369(9578), 2021-2029 (2007).
14. Ghedin E, Wang S, Spiro D et al. Draft genome of the filarial nematode parasite Brugia malayi. Science 317(5845), 1756-1760 (2007).
15. Behm CA, Bendig MM, McCarter JP, Sluder AE. WHO/TDR Scientific working group on 'RNA interference as a means of identifying drug targets for filariasis', report. Tropical Disease Research Publication. World Health Organization (2004).
16. Hoerauf A. New strategies to combat filariasis, Expert Rev. Anti. Infect. Ther. 4(2), 211-222 (2006).
17. World Health Organization. Global Programme to Eliminate Lymphatic Filariasis. Progress report on mass drug administration in 2008. Weekly Epidemiological Record 42, 437-444 (2009).
18. World Health Organization Annual Report on Lymphatic Filariasis 2001. World Health Organization, Geneva, Switzerland (2002).
19. World Health Organization. Annual Report on Lymphatic Filariasis 2002. World Health Organization, Geneva, Switzerland (2003).
20. World Health Organization. Annual Report on Lymphatic Filariasis 2003. World Health Organization, Geneva, Switzerland (2004).
21. World Health Organization Global Programme to Eliminate Lymphatic Filariasis. Progress report for 2004. Weekly Epidemiological Record 80202-80212 (2005).
22. World Health Organization Global Programme to Eliminate Lymphatic Filariasis. Progress report on mass drug administrations in 2005. Weekly Epidemiological Record 22, 221-232 (2006).
23. World Health Organization Global Programme to Eliminate Lymphatic Filariasis. Progress report on mass drug administration in 2006. Weekly Epidemiological Record 82, 361-380 (2007).
24. World Health Organization Global Programme to Eliminate Lymphatic Filariasis. Progress report on mass drug administration in 2007. Weekly Epidemiological Record 83, 333-348 (2008).
25. Hotez PJ, Kamath A. Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and diseaseburden. PLoS Negl. Trop. Dis. 3(8), E412 (2009).
26. Weil GJ, Ramzy RM, Chandrashekar R, Gad AM, Lowrie RC Jr, Faris R. Parasite antigenemia without microfilaremia in bancroftian filariasis. Am. J. Trop. Med. Hyg. 55(3), 333-337 (1996).
27. Chulerek P, Desowitz RS. A simplified membrane filtration technique for the diagnosis of microfilaraemia. J. Parasitol. 56(3), 23-26 (1970).
28. Weil GJ, Ramzy RMR. Diagnostic tools for filariasis elimination programs. Trends Parasitol. 23(214), 78-82 (2006).
29. Lipner EM, Dembele N, Souleymane S et al. Field applicability of a rapid-format anti-Ov-16 antibody test for the assessment of onchocerciasis control measures in regions of endemicity. J. Infect. Dis. 194(2), 216-221 (2006).
30. Weil GJ, Steel C, Liftis F, Li BW, Mearns G, Lobos E. A rapid-format antibody card test for diagnosis of onchocerciasis. J. Infect. Dis. 182(6), 1796-1799 (2000).
31. Nde PN, Pogonka T, Bradley JE, Titanji VP, Lucius R. Sensitive and specific serodiagnosis of onchocerciasis with recombinant hybrid proteins. Am. J. Trop. Med. Hyg. 66(5), 566-571 (2002).
32. Rodríguez-Pérez MA, Domínguez-Vázquez A et al. Antibody detection tests for Onchocerca volvulus: comparison of the sensitivity of a cocktail of recombinant antigens used in the indirect enzyme-linked immunosorbent assay with a rapid-format antibody card test. Trans. R. Soc. Trop. Med. Hyg. 97(5), 539-541 (2003).
33. Ayong LS, Tume CB, Wembe FE, Simo G, Asonganyi T, Lando G. Development and evaluation of an antigen detection dipstick assay for the diagnosis of human onchocerciasis. Trop. Med. Int. Health. 10(3), 228-233 (2005).
34. Boatin BA, Toé L, Alley ES, Dembélé N, Weiss N, Dadzie KY. Diagnostics in onchocerciasis: future challenges. Ann. Trop. Med. Parasitol. 92(1), S41-S45 (1998).
35. Stingl P, Ross M, Gibson DW et al. A diagnostic 'patch test' for onchocerciasis using topical diethylcarbamazine. Trans. R. Soc. Trop. Med. Hyg. 78(2), 254-258 (1984).
36. Duerr HP, Raddatz G, Eichner M. Diagnostic value of nodule palpation in onchocerciasis. Trans. R. Soc. Trop. Med. Hyg. 102(2), 148-154 (2008).
37. Amaral F, Dreyer G, Silva JF, Noroes J, Cavalcanti A, Samico SC et al. Adult worms detected by ultrasonography in human bancroftian filariasis. Am. J. Trop. Med. Hyg. 50(6), 753-757 (1994).
38. Dreyer G, Addiss D, Noroes J, Amaral F, Rocha A, Coutinho A. Ultrasonographic assessment of the adulticidal efficacy of repeat high-dose ivermectin in bancroftian filariasis. Trop. Med. Int. Health 1(4), 427-432 (1996).
39. Freedman DO, de Almeida Filho PJ, Besh S, Maia e Silva MC, Braga C, Maciel A. Lymphoscintigraphic analysis of lymphatic abnormalities in symptomatic and asymptomatic human filariasis. J. Infect. Dis. 170(4), 927-933 (1994).
40. Mand S, Debrekyei YM, Debrah A et al. Frequent detection of worm movements in onchocercal nodules by ultrasonography. Filaria J. 4(1), 2884-12881 (2005).
41. Hewitt RI, White E, Waiace WS, Stewart HW, Kushner S, Subba RY. Experimental chemotherapy of filariasis. II. Effect of piperazine derivatives against naturally acquired filarial infections in cotton rats and dogs. J. Lab. Clin. Med. 32(11), 1300-1313 (1947).
42. Molyneux DH, Bradley M, Hoerauf A, Kyelem D, Taylor MJ. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol. 19(11), 516-522 (2003).
43. Hawking F, Laurie W. Action of hetrazan on filariasis and onchocerciasis. Lancet 2(242), 146-147 (1949).
44. Vickery AC, Nayar JK, Tamplin ML. Diethylcarbamazine-mediated clearance of Brugia pahangi microfilariae in immunodeficient nude mice. Am. J. Trop. Med. Hyg. 34(3), 476-483 (1985).
45. Maizels RM, Denham DA. Diethylcarbamazine (DEC): immunopharmacological interactions of an anti-filarial drug. Parasitology 105(Suppl.), S49-S60 (1992).
46. Misra S, Singh DP, Chatterjee RK. Studies on alteration in antibody level of filarious host following diethylcarbamazine therapy. Trop. Med. 30(1), 1-11 (1988).
47. Stolk WA, Oortmarssen GJV, Pani SP et al. Effects of ivermectin and diethylcarbamazine on microfilariae and overall microfilaria reduction in bancroftian filariasis. Am. J. Trop. Med. Hyg. 73(5), 881-887 (2005).
48. Subramanian S, Vanamail P, Das PK, Pani SP, Ravi R. Randomized controlled clinical trials of antifilarial drugs for lymphatic filariasis: endpoints of outcome measures influence drug efficacy. Presented at: Proceedings of the 23rd Conference of the Indian Society for Medical Statistics, Jawaharlal Nehru Medical college, Belgaum, India. 19-21 January 2005.
49. Piessens W, Beldekas M. Dietylcarbamazine enhances antibody-mediated cellular adherence to Brugia malayi microfilariae. Nature 282(5741), 845-847 (1979).
50. Chen TT. Demonstration of macrofilaricidal action of Hetrazan, antimony and arsenic preparations in man. Chinese Med. J. 83, 625-640 (1964).
51. Silva JF, Jungmann P, Noroes J et al. Histological evidence for adulticidal effect of low doses of diethylcarbamazine in bancroftian filariasis. Trans. R. Soc. Trop. Med. Hyg. 90(2), 192-194 (1996).
52. Noroes J, Dreyer G, Santos A, Mendes VG, Medeiros Z, Addiss D. Assessment of the efficacy of diethylcarbamazine on adult Wuchereria bancrofti in vivo. Trans. R. Soc. Trop. Med. Hyg. 91(1), 78-81 (1997).
53. Chippaux JP, Boussinesq M, Gardon J et al. Severe adverse reaction risk during mass treatment with ivermectin in loiasis-endemic areas. Parasitol. Today 12(11), 448-450 (1996).
54. Lammie P, Milner T, Houston R. Unfulfilled potential: using diethylcarbamazine-fortified salt to eliminate lymphatic filariasis. Bull. World Health Organ. 85(7), 545-549 (2007).
55. Houstan R. Salt fortified with diethylcarbamazine (DEC) as an effective intervention for lymphatic filariasis, with lessons learned from salt iodization programmes. Parasitology 121(Suppl. 1), S161-S173 (2000).
56. Woodruff HB, Burg RW. The antibiotics explosion. In: Discoveries in Pharmacology (Volume 3). Elsevier, Amsterdam, The Netherlands, 338-341 (1986).
57. Aziz MA, Diallo S, Diop IM et al. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet 2(8291), 171-173 (1982).
58. Diallo S, Aziz MA, Lariviere M et al. A double-blind comparison of the efficacy and safety of ivermectin and diethycarbamazine in a placebo controlled study of Senegalese patients with onchocerciasis. Trans. R. Soc. Trop. Med. Hyg. 80(6), 927-934 (1986).
59. Addis DG, Beach MJ, Streit TG et al. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet 350(9076), 480-484 (1997).
60. Ismail MM, Jayakody RL, Weil GJ et al. Efficacy of single dose combinations of albendazole, ivermectin and diethycarbamazine for the treatment of bancroftian filariasis. Trans. R. Soc. Trop. Med. Hyg. 92(1), 94-97 (1997).
61. Thylefors B. Eliminating onchocerciasis as a public health problem. Trop. Med. Int. Health 9(4), A1-A3 (2004).
62. Cully DF, Vassilatis DK, Liu KK et al. Cloning of an avermectin-sensitive glutamate gated chloride channel from Caenorhabditis elegans. Nature 371(6499), 707-711 (1994).
63. Yates DM, Portillo V, Wolstenholme AJ. The avermectin receptors of Haemonchus contortus and Caenorhabditis elegans. Int. J. Parasitol. 33(11), 1183-1193 (2003).
64. Arena JP, Liu KK, Paress PS, Schaeffer JM, Cully DF. Expression of a glutamate-activated chloride current in Xenopus oocytes injected with Caenorhabditis elegans RNA: evidence for modulation by avermectin. Brain Res. 15(3-4), 339-348 (1992).
65. Omura S. Mode of action of avermectin. In: Macrolide Antibiotics: Chemistry, Biology and Practice. Academic Press, NY, USA 571-576 (2002).
66. Feng XP, Hayashi J, Beech RN, Prichard RK. Study of the nematode putative GABA type-A receptor subunits: evidence for modulation by ivermectin. J. Neurochem. 83(4), 870-878 (2002).
67. Sheriff JC, Kotze AC, Sangster NC, Hennessy DR. Effect of ivermectin on feeding by Haemonchus contortus in vivo. Vet. Parasitol. 128(3-4), 341-346 (2005).
68. Hennesy DR, Alvinerie MR. Pharmacokinetics of the macrocyclic lactones: conventional wisdom and new paradigms. In: Macrocyclic Lactones in Antiparasite Therapy. CABI Publishing, NY, USA, 97-124 (2002).
69. Lustigman S, McCarter JP. Ivermectin resistance in Onchocerca volvulus: toward a genetic basis. PLoS Negl. Trop. Dis. 1(1), E76 (2007).
70. Eng JK, Blackhall WJ, Osei-Atweneboana MY, Bourguinat C, Galazzo D, Beech RN. Ivermectin selection on beta-tubulin: evidence in Onchocerca volvulus and Haemonchus contortus. Mol. Biochem. Parasitol. 150(2), 229-235 (2006).
71. Wolstenholme AJ, Fairweather I, Prichard R, von Himmelstjerna GS, Sangster NC. Drug resistance in veterinary helminths. Trends Parasitol. 20(10), 469-1447 (2004).
72. Njue AI, Hayashi J, Kinne L, Feng XP, Prichard RK. Mutations in the extracellular domains of glutamate-gated chloride channel a3 and b subunits from ivermectin-resistant Cooperia oncophora affect agonist sensitivity. J. Neurochem. 89(5), 1137-1147 (2004).
73. Mak JW, Sim BKL, Yen, PKF. Filaricidal effect of albendazole against subperiodic Brugia malayi infection in the leaf-monkey Presbytis melalophos. Trop. Biomed. 1, 121-123 (1984).
74. Horton J. The development of albendazole for lymphatic filariasis. Ann. Trop. Med. Parasitol. 103(7), 33-40 (2009).
75. Jayakody RL, De Silva CSS, Weerasinghe WMT. Treatment of bancroftian filariasis with albendazole: evaluation of efficacy and adverse reactions. Trop. Biomed. 10, 19-24 (1993).
76. Horton RJ. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop. 64(1-2), 79-93 (1997).
77. Addiss D, Gamble CL, Garner P, Gelband H, Ejere HOD, Critchley JA, International Filariasis Review Group. Albendazole for lymphatic filariasis. Cochrane Database Syst. Rev. 4 (2005).
78. Wah MJ, Zaman V, Sivanandam S. Antifilarial activity of levamisole hydrochloride against subperiodic Brugia malayi infection of domestic cats. Am. J. Trop. Med. Hyg. 23(3), 369-374 (1974).
79. Singhal KC, Saxena PN. Antifilarial activity of levamisole hydrochloride on Setaria cervi. Indian J. Phar. 10(4), 309-314 (1978).
80. Singh DP, Misra S, Chatterjee RK. Response of Dipetalonema viteae in Mastomys natalensis to some known antifilarials. Indian J. Exp. Biol. 26(1), 48-52 (1988).
81. Misra S, Chatterjee RK, Sen AB. The response of L.carinii to antifilarial agents in cotton rats (Sigmodon hispidus) and multimammate rat (Mastomys natalensis) Indian J. Med. Res. 79, 749-754 (1984).
82. Natarajan PN, Zaman V, Yeoh TS. In vitro activity of levamisole on the infective larvae, microfilariae and adult worms of Breinlia sergenti. Int. J. Parasitol. 4(2), 207-210 (1974).
83. Pandaya U, Shukla OP. Suramin destabilizes the secondary structure of filarial DNA. Med. Sci. Res. 22, 833-834 (1994).
84. Walter RD, Schulz-Kay H. Onchocerca volvulus: effect of suramin on lactate dehydrogenase and malate dehydrogenase. Tropenmed. Parasitol. 31 (1), 55-58 (1980).
85. Walter RD, Albiez EJ. Inhibition of NADP-linked malic enzyme from Onchocerca volvulus and Dirofilaria immitis by suramin. Mol. Biochem. Parasite 4(1-2), 53-60 (1981).
86. World Health Organization. Model Prescribing Information: Drugs Used in Parasitic Diseases, 2nd Edition. WHO, Geneva, Switzerland (1995)
87. Chijioke CP, Umeh RE, Mbah AU, Nwonu P, Fleckenstein LL, Okonkwo OO. Clinical pharmacokinetics of suramin in patients with onchocerciasis. Eur. J. Clin. Pharmacol. 54(3), 249-251 (1998).
88. Mak JW, Lam PL, Choong MF, Suresh K. Antifilarial activity of intravenous suramin and oral diethylcarbamazine citrate on subperiodic Brugia malayi in the leaf-monkey, Presbytis cristata. J. Helminthol. 64(2), 96-99 (1990).
89. Carme B, Lenoble DR, Smith M, Pontal P, Gentilini M. Litomosoides carinii infection in cotton-rats: evolution of microfilaraemia before and after treatment with diethylcarbamazine and suramin. Trans. R. Soc. Trop. Med. Hyg. 75(3), 418-420 (1981).
90. Howells RE, Mendis AM, Bray PG. The mode of action of suramin on the filarial worm Brugia pahangi. Parasitology. 87(1), 29-48 (1983).
91. Schares G, Hofmann B, Zahner H. Antifilarial activity of macrocyclic lactones: comparative studies with ivermectin, doramectin, milbemycin A4 oxime, and moxidectin in Litomosoides carinii, Acanthocheilonema viteae, Brugia malayi, and B. pahangi infection of Mastomys coucha. Trop. Med. Parasitol. 45(2), 97-106 (1994).
92. Molyneux DH, Bradley M, Hoerauf A, Kyelem D, Taylor MJ. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol. 19 (11), 516-522 (2003).
93. Chen YC, Hung YP, Fleckenstein L. Liquid chromatographic assay of Moxidectin in human plasma for application to pharmacokinetic studies. J. Pharm. Biomed. Anal. 29(5), 917-926 (2002).
94. Forrester SG, Prichard RK, Beech RN. A glutamate-gated chloride channel subunit from Haemonchus contortus: expression in a mammalian cell line, ligand binding, and modulation of anthelmintic binding by glutamate. Biochem. Pharmacol. 63(6), 1061-1068 (2002).
95. Cully DF, Vassilatis DK, Liu KK et al. Cloning of an avermectin-sensitive glutamate gated chloride channel from Caenorhabditis elegans. Nature 371(6499), 707-711 (1994).
96. Blackhall WJ, Pouliot JF, Prichard RK, Beech RN. Haemonchus contortus: selection at a glutamate-gated chloride channel gene in ivermectin and Moxidectin selected strains. Exp. Parasitol. 90(1), 42-48 (1998).
97. Zulalian J, Stout SJ, daCunha AR, Garces T, Miller P. Absorption, tissue distribution, metabolism, and excretion of moxidectin in cattle. J. Agric. Food Chem. 42(2), 381-387 (1994).
98. Cotreau MM, Warren S, Ryan JL et al. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans, J. Clin. Pharmacol. 43 (10), 1108-1115 (2003).
99. Evans DB, Gelband H, Vlassoff C. Social and economic factors and the control of lymphatic filariasis: a review. Acta Trop. 53(1), 1-26 (1993).
100. Gyapong JO, Gyapong M, Evans DB, Aikins MK, Adjei S. The economic burden of lymphatic filariasis in northern Ghana. Ann. Trop. Med. Parasitol. 90(1), 39-48 (1996)
101. Ramaiah KD, Radhamani MP, John KR et al. The impact of lymphatic filariasis on labour inputs in southern India: results of a multi-site study. Ann. Trop. Med. Parasitol. 94(4), 353-364 (2000).
102. Haddix AC, Kestler A. Lymphatic filariasis: economic aspects of the disease and programmes for its elimination. Trans. R. Soc. Trop. Med. Hyg. 94 (6), 592-593 (2000).
103. Molyneux DH, Taylor MJ. Current status and future prospects of the Global Lymphatic Filariasis Programme. Curr. Opin. Infect. Dis. 14 (2), 155-159 (2001).
104. Behbehani K. Candidate parasitic diseases. Bull. WHO 76 (2), 64-67 (1998).
105. World Health Organization. Elimination of lymphatic filariasis as a public health problem. WHO, WHA, Geneva (1997).
106. Caffrey CR. Chemotherapy of schistosomiasis: present and future. Curr. Opin. Chem.Biol. 11(4), 433-439 (2007).
107. Fox LM. Ivermectin: uses and impact 20 years on. Curr. Opin. Infect. Dis. 19(6), 588-593 (2006).
108. Udall DN. Recent updates on onchocerciasis: diagnosis and treatment. Clin.Infect.Dis. 44(1), 53-60 (2007).
109. Solomon AW, Holland MJ, Alexander ND, Massae PA, Aguirre A, Natividad-Sancho A et al. Mass treatment with single-dose azithromycin for trachoma. N. Enfl. J. Med. 351(19), 1962-1971 (2004).
110. Lansdown R, Ledward A, Hall A et al. Schistosomiasis, helminth infection and health education in Tanzania: achieving behavior change in primary schools. Health Educ.Res. 17(4), 425-433 (2002).
111. Chodakewitz J. Ivermectin and lymphatic filariasis: a clinical update. Parasitology Today. 11(6), 233-235 (1995).
112. Dreyer G, Coutinho A, Miranda D et al. Treatment of bancroftian filariasis in Recife, Brazil: a two year comparative study of the efficacy of single treatments with ivermectin or diethvlcarbamazine. Trans. R. Soc. Trop. Med. Hyg. 89(1), 98-102(1995).
113. Mectizan Donation Programme. Annual Highlights, the Accomplishments of the Mectizan Donation Program in its 19th Year. Mectizan Donation Program, GA, USA (2007).
114. Bockarie MJ, Alexander NDE, Hyun P et al. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes. Lancet 351(9097), 162-168 (1998).
115. Addiss DG, Beach MJ, Streit TG et al. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet. 350(9083), 480-484 (1997).
116. Rajendran R, Sunish IP, Mani TR et al. Impact of two annual single-dose mass drug administrations with diethylcarbamazine alone or in combination with albendazole on Wuchereria bancrofti microfilaraemia and antigenaemia in South India. Trans. R. Soc. Trop. Med. Hyg. 98(3), 174-181 (2004).
117. Rajendran R, Sunish IP, Mani TR et al. Community-based study to assess the efficacy of DEC plus ALB against DEC alone on bancroftian filarial infection in endemic areas in Tamil Nadu, south India. Trop. Med. Int. Health. 11(6), 851-861 (2006).
118. Awadzi K, Edwards G, Duke BOL et al. The co-administration of ivermectin and albendazole-safety, pharmacokinetics and efficacy against Onchocerca volvulus. Ann. Trop. Med. Parasitol. 97(2), 165-178 (2003).
119. Makunde WH, Kamugisha LM, Massaga JJ et al. Treatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared with treatment of single infection with bancroftian filariasis. Filaria J. 2(1), 15 (2003).
120. Bazzocchi C, Mortarino M, Grandi G et al. Combined ivermectin and doxycycline treatment has microfilaricidal and adulticidal activity against Dirofilaria immitis in experimentally infected dogs. Int. J. Parasitol. 38(12), 1401-1410 (2008).
121. Debrah AY, Mand S, Specht S et al. Doxycycline reduces plasma VEGF-C/ sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog. 2(9), 829-843 (2006).
122. Hoerauf A, Specht S, Büttner M et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med. Microbiol. Immunol. 197 (3), 295-311 (2008).
123. Kraker MEAD, Stolk WA, Van Oortmarssen GJ, Habbema JDF. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti. Trop. Med. Int. Health 11(5), 718-728 (2006).
124. Behm CA, Bendig MM, McCarter JP, Sluder AE. WHO/TDR Scientific working group on 'RNA interference as a means of identifying drug targets for filariasis'. Report DOI:WHO/PRD/RNAi (2004) (Epub ahead of print).
125. Ottesen EA, Hooper PJ, Bradley M, Biswas G. The Global Programme to Eliminate Lymphatic Filariasis: health impact after 8 years. PLoS Negl. Trop. Dis. 2(10), E317 (2008).
126. McGregor et al. Control of filariasis with hetrazan. Br. Med. J. 2(4790), 908-911 (1952).
127. Otto GF, Jachowski LA, Wharton JD. Filariasis in American Samoa. III. Studies on chemotherapy against the non periodic form of Wuchereria bancroftii. Am. J. Trop. Med. Hyg. 2(3), 495-516 (1953).
128. Ashburn LL, Burch TA, Brady FJ. Pathologic effects of suramin, hetrazan and arsenamide on adult Onchocerca volvulus. Bol. Oficina Sanit. Panam. 28(11), 1107-1117 (1949).
129. Rogers L. Further work on antimony intravenously in filariasis. Br. Med. J. 1(3096), 596-598 (1920).
130. Friedheim EAH. MSbB in the treatment of bancroftian filariasis. Trans. R. Soc. Trop. Med. Hyg. 56(3), 236-240 (1962).
131. Rao RU, Huang Y, Fischer K, Fischer PU, Weil GJ. Brugia malayi: Effects of nitazoxanide and tizoxanide on adult worms and microfilariae of filarial nematodes. Exp. Parasitol. 121(1), 38-45 (2009).
132. Singh BK, Mishra M, Saxena N, Yadav GP, Maulik PR, Tripathi RP. Synthesis of 2-sulfanyl-6-methyl-1,4-dihydropyrimidines as a new class of antifilarial agents. Eur. J. Med. Chem.43(12), 2717-2723 (2008).
133. Katiyar SB, Bansal I, Saxena JK, Chauhan PMS. Synthesis of 2,4,6-trisubstituted pyrimidine derivatives as a new class of antifilarial topoisomerase II inhibitor. Bioorg. Med. Chem. Lett. 15, 47-50 (2005).
134. Lacey E. Mode of action of benzimidazole. Parasitol. Today 6(4), 112-115 (1990).
135. Sadjjadi SM, Alborzi AW, Mostovfi H. Comparative clinical trial of mebendazole and metronidazole in giardiasis of children. J. Trop. Pediatr. 47(3), 176-178 (2001).
136. Hoegaerden MV, Ivanoff B, Flocard F, Salle A, Chabaud B. The use of mebendazole in the treatment of filariasis due to Loa loa and Monsonella perstans. Ann. Trop. Med. Parasitol. 81(3), 275-282 (1987).
137. Dallah CN, Hoffmann W, Rapp J, Okonkwo PO, Schulzkey H. The efficacy of umf-078 on acanthocheilonema-viteae and litomosoides-sigmodontis in meriones-unguiculatus. Parasite J. Soc. Fr. Parasitol. 1, 37-39 (1994).
138. Reddy AB, Rao UR, Chandrashekar R, Shrivastava R, Subrahmanyam D. Comparative efficacy of some benzimidazoles and amoscanate (go-9333) against experimental filarial infections. Tropenmedizin Und Parasitologie. 34(4), 259-262 (1983).
139. Kreckhoven IV, Kumar V. Macrofilaricidal activity of oral flubendazole on Brugia pahangi. Trans. R. Soc. Trop. Med. Hyg. 82(6), 890-891 (1988).
140. Makawy AE, Radwan HA, Ghaly IS, El-Raouf AA. Genotoxical, teratological and biochemical effects of anthelmintic drug oxfendazole maximum residue limit (MRL) in male and female mice. Reprod. Nutr. Dev. 46(2), 139-156 (2006).
141. Huang NJ, Cerepnalkoski L, Nwankwo JO, Dews M, Landolph JR. Induction of chromosomal-aberrations, cytotoxicity, and morphological transformation in mammalian-cells by the antiparasitic drug flubendazole and the antineoplastic drug harringtonine. Fundam. Appl. Toxicol. 22(2), 304-331 (1994).
142. Abuzar S, Sharma S, Fatma N et al. Studies on potential filaricides Part 18: synthesis of 2,2́ dicarbomethoxyl amino 5-5́ dibenzimidazolyl ketone and related compounds as potential anthelmintics. J. Med. Chem. 29(7), 1296-1299 (1986).
143. Dubey R, Abuzar S, Sharma S, Chatterjee RK, Katiyar JC. Synthesis and anthelmintic activity of 5(6)-(benzimidazol-2-y-lcarbamoyl) and (4-substituted piperazin-1- yl)benzimidazoles. J. Med. Chem. 28(11), 1748-1750 (1985).
144. Ram S, Skinner M, Kalvin D et al. Synthesis of potential antifilarial agents. 1-(5-Benzoylbenzimidazol-2-yl)-3-alkyl-and-arylureas. J.Med.Chem. 27(7), 914-917 (1984).
145. Ram S, Wise DS, Wotring LL, McCall JW, Townsend LB. Synthesis and biological activity of certain alkyl 5-(alkoxycarbonyl)- 1H-benzimidazole-2- carbamates and related derivatives: a new class of potential antineoplastic and antifilarial agents. J. Med. Chem. 35(3), 539-547 (1992).
146. Pani SP, Reddy GS, Das LK et al. Tolerability and efficacy of single dose of albendazole or diethylcarbamazine(DEC) or coadministration of albendazole with DEC in the clearance of Wuchereria bancrofti microfilria carriers in pondicherry, south India: hospital based study. Filaria J. (1)1, 2881-2881 (2002).
147. Tripathi R, Bhaduri AP, Singh SN, Chatterjee RK, Murthy PK. Antifilarial activity of some 2H-1-benzopyran-2-ones (coumarins). Acta. Trop. 76(2), 101-106 (2000).
148. Tripathi RP, Tewari VK, Bhattacharya S, Tyagi K, Srivastava VML, Murthy PK. 7-O-[4-methyl piperazine-1-(2-acetyl)]-2H-1- benzopyran-2-one: a novel antifilarial lead compound. Acta. Trop. 87(2), 215-224 (2003).
149. Katiyar D, Tewari VK, Tripathi RP, Reddy VM, Bhattacharya SM, Saxena J K. Synthesis and antifilarial evaluation of 7-O-acetamidyl- 4-alkyl-2H-1- benzopyran-2-ones. Arzneim- Forsch/Drug Res. 53, 857 (2003).
150. Bhattacharya S, Katiyar D, Bajpai P, Tripathi RP, Saxena JK. 4-methyl-7-(tetradecanoyl)- 2H-1-benzopyran-2-one: a novel DNA topoisomerase II inhibitor with adulticidal and embryostatic activity against sub-periodic Brugia malayi. Parasitol. Res. 92(3), 177-182 (2004).
151. Bose C, Agarwal SK, Chatterjee RK, Srivastava VML. Carboline antifilarials: Effects on carbohydrate metabolizing enzymes in Litomosides carinii female. Indian J. Exp. Biol. 32(6), 431-434 (1994).
152. Chandra M, Sahay AN, Pandey DS et al. Potential inhibitors of DNA topoisomerase II: ruthenium(II) poly-pyridyl and pyridyl-azine complexes. J. Organomet. Chem. 689(13), 2256-2267 (2004).
153. Kumar P, Agarwal SK, Bhakuni DS. Antiparasitic agents: part XI - synthesis and anthelmintic activity of 6-/8-[(2-carbomethoxyamino) benzimidazole]-5-carbonylamino-1- substituted-9H-pyrido [3,4-b]indoles. Indian J. Chem. 29B, 1077-1088 (1990).
154. Kapoor S, Singhal KC. 5/6/7/8 mono or disubstituted 1H/1-phenyl-9H-pyrido [3, 4 b] indoles-a new class of antifilarial agents and their relationship with voltage sensitive calcium channels in Setaria cervi. Indian J. Exp. Biol. 36(9), 887-890 (1998).
155. Srivastava S, Agarwal A, Chauhan PMS. Potent 1,3-disubstituted 9H-pyrido[3,4-b] indoles as new lead compounds in antifilarial chemotherapy. J. Med. Chem. 42(9), 1667-1672 (1999).
156. Sundberg RJ, Biswas S, Murthi K, Rowe D, McCall JW, Dzimianski MT. Bis-cationic heteroaromatics as macrofilaricides: synthesis of bis-amidine and bis-guanylhydrazone derivatives of substituted imidazo[1,2-a] pyridines. J. Med. Chem. 41(22), 4317-4328 (1998).
157. Agarwal A, Agarwal SK, Singh SN, Fatma N, Chatterjee RK. Synthesis of neoeudistomin analogs-as potential filaricides. Bioorg. Med. Chem. Lett. 5(14), 1545-1548 (1995).
158. Kumar Y, Green R, Wise DS, Wotring LL, Townsend LB. Synthesis of 2, 4-disubstituted thiazoles and selenazoles as potential antifilarial and antitumor agents. 2. 2-arylamido and 2-alkylamido derivatives of 2-amino-4-(isothiocyanatomethyl) thiazole and 2-amino-4-(isothiocyanatomethyl) selenazole. J. Med. Chem. 36(24), 3849-3852 (1993).
159. Kumar Y, Green R, Borysko KZ, Wise DS, Wotring LL, Townsend LB. Synthesis of 2,4-disubstituted thiazoles and selenazoles as potential antitumor and antifilarial agents. 1. Methyl 4-(isothiocyanatomethyl) thiazole-2- carbamates, -selenazole-2-carbamates, and related derivatives. J. Med. Chem. 36(24), 3843-3848 (1993).
160. Srivastava SK, Chauhan PMS, Bhaduri AP, Fatima N, Chatterjee RK. Quinolones: novel probes in antifilarial chemotheraphy. J. Med. Chem. 43(11), 2275-2279 (2000).
161. Srivastava S, Haq W, Murthy PK, Chauhan PMS. Solid phase synthesis of quinolones. Bioorg. Med. Chem. Lett. 9, 1885 (1999).
162. Srivastava SK, Chauhan PMS, Agarwal SK et al. Syntheses and antifilarial profile of 5-amino and 5,8-diamino-isoquinoline derivatives: A new class of antifilarial agents. Bioorg. Med. Chem. Lett. 6, 2623 (1996).
163. Tewari S, Chauhan PMS, Bhaduri AP, Fatima N, Chatterjee RK. Synthesis and antifilarial profile of 7-chloro-4-(substituted amino) quinolines: a new class of antifilarial agents. Bioorg. Med. Chem. Lett. 10, 1409 (2000).
164. Tewari S, Chauhan PMS, Bhaduri AP et al. 1,1́-dicyano-2-substituted ethylenes: a new class of glucose uptake inhibitors in antifilarial chemotherapy. Bioorg.Med. Chem. Lett. 7(14), 1891-1896 (1997).
165. Chauhan PMS, Chatterjee RK. Synthesis of 1,3-substituted indoles, 2,4,6-substituted-s-triazines and 4,5-substituted pyrazoles as possible antifilarial agents. Indian J. Chem. 33B, 32. (1994).
166. Srivastava S, Chauhan PMS, Bhaduri AP, Murthy PK, Chatterjee RK. Secondary amines as new pharmacophores for macrofilaricidal drug design. Bioorg. Med. Chem. Lett.10, 313 (2000).
167. Brienne MJ, Varech D, Leclercq M et al. New antifilarial agents.I. Epoxysulphonamide and ethylene sulphonamides. J. Med. Chem. 30(12), 2232 (1987).
168. Radembino N, Loiseau PM, Dessalles MC et al. Epoxyethane-/ ethynesulfonamides with antifilarial activities. Degradation kinetics and inhibitory effect on filarial malate dehydrogenase and lactate dehydrogenase. Arzneim-Forsch/Drug Res. 48(3), 294-299 (1998).
169. Pandya U, Saxena JK, Kaul SM et al. DNA topoisomerases of filarial parasites: effect of antifilarial compounds. Med. Sci. Res. 27(2), 103-106 (1999).
170. Srivastava AK, Tripathi RP, Khan AR, Bhaduri AP. Effect of 3-O- (aminoalkyl)- a-d-gluco (xylo) furanoses on glutathione metabolism of falarial parasites. Helminthol. 32, 25 (1995).
171. Khan AR, Tripathi RP, Bhaduri AP et al. Synthesis and immunomodulatory activity of 3-O-[2́-hydroxy-3́-N,N-disubstituted aminopropan-1́-yl]-a-d-glucofuranoses. Eur. J. Med. Chem. 36(5), 435-445 (2001).
172. Tripathi RP, Rastogi SK, Kundu B et al. Identification of inhibitors of
173. Khan AR, Tripathi RP, Tiwari VK, Mishra RC, Reddy VJM, Saxena JK. Conjugate addition of amines to sugar derived olefinic ester: synthesis of glycosylated amino esters as DNA topoisomerase-II inhibitors. J. Carbohydr. Chem. 21(6), 591-604 (2002).
174. Verma RS, Shukla A, Chatterjee RK . Evaluation of vanillic acid analogues as a new class of antifilarial agents. Indian J. Exp. Biol. 31(10), 819-821 (1993).
175. Loiseau PM, Depreux P. In vivo antifilarial evaluation of phenoxycyclohexane derivatives. Ann. Trop. Med. Parasitol. 87(5), 469-476 (1993).
176. Loiseau PM, Jaffe JJ, Craciunescu DG. In vitro antifilarial activity of organometallic complexes against infective larvae of Molinema dessetae and adult females of Brugia pahangi. Int. J. Parasitol. 28(8), 1279-1282 (1998).
177. Tagboto SK, Townson S. Onchocera volvulus and O. lienalis: the micofiracidal activity of moxidectin compared with that of invermectin in vitro in vivo. Ann. Trop. Med. Parasitol. 90(5), 497-505 (1996).
178. Loiseau PM, Bourass J, Letourneux Y. Lymphotropic antifilarial agents derived from closantel and chlorambucil. Int. J. Parasitol. 27(4), 443-447 (1997).
179. Elkihel L, Loiseau PM, Bourass J, Gayral P, Letourneux Y. Synthesis and orally macrofilaricidal evaluation of niclosamide lymphotropic prodrugs. Arzneim- Forsch/Drug Res. 44(11), 1259-1264 (1994).
180. Omura S, Miyadera H, Ui H et al. An anthelmintic compound, nafuredin, shows selective inhibition of complex I in helminth mitochondria. Proc. Natl. Acad. Sci. USA. 98(1), 60-62 (2001).
181. Capon RJ, Colin Skene C, Liu EH et al. Nematocidal thiocyanatins from a Southern Australian marine sponge Oceanapia sp. J. Nat. Prod. 67(8), 1277-1282 (2004).
182. Lakshmi V, Kumar R, Gupta P et al. The antifilarial activity of a marine red alga, Botryocladia leptopoda, against experimental infections with animal and human filariae. Parasitol. Res. 93(6), 468-474 (2004).
183. Lakshmi VB, Saxena A, Pandey K, Bajpai P, Bhattacharya SM. Antifilarial activity of Zoanthus species (Phylum Coelenterata, class Anthzoa) against human lymphatic filaria, Brugia malayi. Parasitol. Res. 93(4), 268-273 (2004).
184. Lakshmi V, Srivastava S, Mishra SK, Misra S, Verma M, Misra-Bhattacharya SM. In vitro and in vivo antifilarial potential of marine sponge, Haliclona exigua (Kirkpatrick), against human lymphatic filarial parasite Brugia malayi: antifilarial activity of H. exigua. Parasitol. Res. 105(5), 1295-1301 2009.
185. Nyasse B, Ngantchou I, Nono JJ, Schneider B. Antifilarial activity in vitro of polycarpol and 3-O-acetyl aleuritolic acid from cameroonian medicinal plants against Onchocerca gutturosa. Nat. Prod. Res. 20 (4), 391-397 (2006).
186. Mathew N, Bhattacharya SM, Perumal V, Muthuswamy K. Antifilarial lead molecules isolated from Trachyspermum ammi. Molecules 13(9), 2156-2168 (2008).
187. Misra N, Sharma M, Raj K, Dangi A, Srivastava S, Misra-Bhattacharya S. Chemical constituents and antifilarial activity of Lantana camara against human lymphatic filariid Brugia malayi and rodent filariid Acanthocheilonema viteae maintained in rodent hosts. Parasitol. Res. 100(3), 439-448 (2007).
188. Singh M, Shakya S, Soni VK, Dangi A, Kumar N, Bhattacharya SM. The n-hexane and chloroform fractions of Piper betle L. trigger different arms of immune responses in BALB/c mice and exhibit antifilarial activity against human lymphatic filarid Brugia malayi. Int. Immunopharmacol. 9(6), 716-728 (2009).
189. Tripathi S, Singh N, Shakya S et al. Landrace/gender-based differences in phenol and thiocyanate contents and biological activity in Piper betle L. Curr. Sci. 91(6), 746-749 (2006).
190. Zahner H, Taubert A, Harder A, Himmelstjerna GS . Filaricidal efficacy of anthelmintically active cyclodepsipeptides. Int. J. Parasitol. 31(13), 1515-1522 (2001).
191. Mugunthu R, Dhananjeyan, Milev Youli P et al. Synthesis and activity of substituted anthraquinones against a human filarial parasite. Brugia malayi. J. Med. Chem. 48(8), 2822-2830 (2005).
192. Tiwari VK, Tewari N, Katiyar D et al. Synthesis and antifilarial evaluation of N1, Nn-xylofuranosylated diaminoalkanes. Bioorg. Med. Chem. 11, 1789 - 1800 (2003).
193. Kalyanasundaram M, Nisha M, Paily KP, Prabakaran G. Synthesis and screening of 1-methyl-4-substituted benzoyl piperazides against adult Setaria digitata for antifilarial activity. Acta Trop. 111(2), 168-171 (2009).
194. Mak JW, Ngah Z, Choong MF, Navaratnam V. Chemotherapeutic effect of CGI 18041 against subperiodic Brugia malayi infection in Presbytis cristata. Trop. Med. Parasitol. 46(1), 6-8 (1995).
195. Kohler P, Davies KP, Zahner H. Activity, mechanism of action and pharmacokinetics of 2-tert-butylbenzothiazole and CGP 6140 (amocarzine) antifilarial drugs. Acta Trop. 51(3-4), 195-211 (1992).
196. Harder A, Samson GV. Himmelstjerna Cyclooctadepsipeptides - a new class of anthelmintically active compounds. Parasitol. Res. 88(6), 481-488 (2002).
197. Harder A, Wrede HPS, Krucken J, Marinovski P, Wunderlich F, Willson J. Cyclooctadepsipeptides - an anthelmintically active class of compounds exhibiting a novel mode of action. Int. J. Antimicrobiol. Agents 22(3), 318-331 (2003).
198. Gupta S, Srivastava AK. Biochemical targets in filarial worms for selective antifilarial drug design. Acta Parasitologica 50(1), 1-18 (2005).
199. Geldhof P, Visser A, Clark D et al. RNA interference in parasitic helminths: current situation, potential pitfalls and future prospects. Parasitology 134(5), 609-619 (2007).
200. Pfarr K, Heider U,Hoerauf A. RNAi mediated silencing of actin expression in adult Litomosoides sigmodontis is specific, persistent and results in a phenotype. Int. J. Parasitol. 36(6), 661-669 (2006).
201. Lustigman S, Zhang J, Liu J, Oksov Y, Hashmi S. RNA interference targeting cathepsin L and Z-like cysteine proteases of Onchocerca volvulus confirmed their esstential function during L3 molting. Mol. Biochem. Parasitol. 138(2), 165-170 (2004).
202. Ford L, Zhang J, Liu J, Hashmi S et al. Functional analysis of the cathepsin-like cysteine protease genes in adult Brugia malayi using RNA Interference. PLoS Negl. Trop. Dis. 3(2), E377 (2009).
203. Aboobaker AA, Blaxter ML. Use of RNA interference to investigate gene function in the human filarial nematode parasite Brugia malayi. Mol. Biochem. Parasitol. 129(1), 41-51 (2003).
204. Ford L, Guiliano DB, Oskov Y et al. Characterization of a novel filarial serine protease inhibitor, Ovi-SPI-1, from Onchocerca volvulus, with potential multifunctional roles during development of the parasite. J. Biol. Chem. 280(49), 40845-40856 (2005).
205. Kang S, Hong YS. RNA Interference in infectious tropical diseases. Korean J. Parasitol. 46(1), 1-15 (2008).
206. Pink R, Hudson A, Mouriès MA, Bendig M. Opportunities and challenges in antiparasitic drug discovery. Nat. Rev. Drug Discov. 4(9), 727-740 (2005).
207. Kumar S, Chaudhary K, Foster JM et al. Mining predicted essential genes of Brugia malayi for nematode drug targets. PLoS ONE. 2(11), 1189 (2007).
208. Frand AR, Russel S, Ruvkun G. Functional genomic analysis of C. elegans molting. PLoS Biol. 3(10), 1719-1733 (2005).
209. Page AP, McCormack G, Birnie AJ. Biosynthesis and enzymology of the Caenorhabditis elegans cuticle: identification and characterization of a novel serine protease inhibitor. Int.J.Parasitol. 36, 681-689 (2006).
210. Koppen M, Simske JS, Sims PA et al. Cooperative regulation of AJM-1 controls junctional integrity in Caenorhabditis elegans epithelia. Nat. Cell Biol. 3, 983-991 (2001).
211. McMahon L, Legouis R, Vonesch JL, Labouesse M. Assembly of C. elegans apical junctions involve positioning and compaction by LET-413 and protein aggregation by the MAGUK protein DLG-1. J. Cell Sci. 114(12), 2265-2277 (2001).
212. Phelan P. Innexins: members of an evolutionarily conserved family of gap junction proteins. Biochim. Biophys. Acta 1711(2), 225-245 (2005).
213. Foster JM, Zhang Y, Kumar S, Carlow CK. Parasitic nematodes have two distinct chitin synthases. Mol. Biochem. Parasitol. 142(1), 126-132 (2005).
214. Harris MT, Lai K, Arnold K, Martinez HF, Specht CA et al. Chitin synthase in the filarial parasite, Brugia malayi. Mol. Biochem. Parasitol. 111(2), 351-362 (2000).
215. Beverley SM, Owens KL, Showalter M et al. Eukaryotic UDP-galactopyranose mutase (GLF gene) in microbial and metazoal pathogens. Eukaryot. Cell. 4(6), 1147-1154 (2005).
216. Kormish JD, McGhee JD. The C. elegans lethal gut-obstructed gob-1 gene is trehalose- 6-phosphate phosphatase. Dev. Biol. 287(1), 35-47 (2005).
217. Zhang Y, Foster JM, Kumar S, Fougere M, Carlow CK. Cofactor independent phosphoglycerate mutase has an essential role in Caenorhabditis elegans and is conserved in parasitic nematodes. J. Biol. Chem. 279 (35), 37185-37190 (2004).
218. MacMorris M, Kumar M, Lasda E et al. A novel family of C. elegans snRNPs contains proteins associated with trans-splicing. RNA. 13(4), 511-520 (2007).
219. Maine EM, Hauth J, Ratliff T et al. EGO-1, a putative RNA-dependent RNA polymerase, is required for heterochromatin assembly on unpaired DNA during C. elegans meiosis. Curr. Biol. 15(21), 1972-1978 (2005).
220. McLaren DJ, Worms MJ, Laurence BR, Simpson MG. Microorganisms in filarial larvae (Nematoda). Trans. R. Soc. Trop. Med. Hyg. 69(5), 509-514 (1975).
221. Kozek WJ. Transovarially-transmitted intracellular microorganisms in adult and larval stages of Brugia malayi. J Parasitol. 63(6), 992-1000 (1977).
222. Kozek WJ, Marroquin HF. Intracytoplasmic bacteria in Onchocerca volvulus. Am. J. Trop. Med. Hyg. 26(4), 663-678 (1977).
223. Sironi M, Bandi C, Sacchi L et al. Molecular evidence for a close relative of the arthropod endosymbiont Wolbachia in a filarial worm. Mol. Biochem. Parasitol. 74(2), 223-227 (1995).
224. Bandi C, Anderson TJ, Genchi C, Blaxter ML. Phylogeny of Wolbachia in filarial nematodes. Proc. R. Soc. Lond. B. Biol. Sci. 265(1413), 2407-2413 (1998).
225. Hoerauf A, Pahle KN, Schmetz C et al. Tetracycline therapy targets intracellular bacteria in the filarial nematode Litomosoides sigmodontis and results in filarial infertility. J. Clin. Invest. 103(1), 11-18 (1999).
226. McGarry HF, Pfarr K, Egerton G et al. Evidence against Wolbachia symbiosis in Loa loa. Filaria J. 2(1), 9 (2003).
227. Bordenstein S, Fitch D, Werren J. Absence of Wolbachia in nonfilariid nematodes. J. Nematol. 35(3), 266-270 (2003).
228. Hoerauf. New strategies to combat filariasis. Expert Rev. Anti. Infect. Ther. 4(2), 211-222 (2006).
229. Foster J, Ganatra M, Kamal I et al. The Wolbachia genome of Brugia malayi: endosymbiont evolution within a human pathogenic nematode. PLoS Biol. 3(4), 599-614 (2005).
230. Taylor MJ, Bandi C, Hoerauf AM, Lazdins J. Wolbachia bacteria of filarial nematodes: a target for control? Parasitol. Today 16(5), 179-180 (2000).
231. Bo Wu, Novelli J, Foster J, Vaisvila R, Conway L, Ingram J et al. The heme biosynthetic pathway of the obligate wolbachia endosymbiont of Brugia malayi as a potential anti-filarial drug target. PLoS Negl. Trop. Dis. 3(7), E475 (2009).
232. Alan L. Scott, Ghedin E. The genome of Brugia malayi - all worms are not created equal. Parasitol. Int. 58(1), 6-11 (2009).
233. Specht S, Mand S, Marfo-Debrekyei Y et al. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitol. Res. 103(6), 1303-1309 (2008).
234. Bosshardt SC, McCall JW, Coleman SU et al. Prophylactic activity of tetracycline against Brugia pahangi infection in jirds (Meriones unguiculatus). J. Parasitol. 79(5), 775-777 (1993).
235. Langworthy NG, Renz A, Mackenstedt U et al. Macrofilaricidal activity of tetracycline against the filarial nematode Onchocerca ochengi: elimination of Wolbachia precedes worm death and suggests a dependent relationship. Proc. R. Soc. Lond. B. Biol. Sci. 267(1448), 1063-1069 (2000).
236. Rao RU, Moussa H, Weil GJ. Brugia malayi: effects of antibacterial agents on larval viability and development in vitro. Exp. Parasitol. 101(1), 77-81 (2002).
237. Casiraghi M, McCall JW, Simoncini L et al. Tetracycline treatment and sex-ratio distortion: a role for Wolbachia in the moulting of filarial nematodes? Int. J. Parasitol. 32(12), 1457-1468 (2002).
238. Rajan TV. Relationship of anti-microbial activity of tetracyclines to their ability to block the L3 to L4 molt of the human filarial parasite Brugia malayi. Am. J. Trop. Med. Hyg. 71(1), 24-28 (2004).
239. Hoerauf A, Mand S, Adjei O, Fleischer B, Buttner DW. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 357(9266 ), 1415-1416 (2001).
240. Hoerauf A, Buttner DW, Adjei O, Pearlman E. Onchocerciasis. BMJ 326(7382), 207-210 (2003).
241. Hoerauf A, Mand S, Fischer K et al. Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med. Microbiol. Immunol. (Berlin) 192(4), 211-216 (2003).
242. Hoerauf A, Mand S, Volkmann L et al. Doxycycline in the treatment of human onchocerciasis: kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect. 5(4), 261-273 (2003).
243. Bajpai P, Verma SK, Katiyar D et al. Search of new prototypes for chemotherapy of filariasis: chemotherapeutic and biochemical approach. Parasitol. Res. 95(6), 383-390 (2005).
244. Shakya S, Bajpai P, Sharma S, Bhattacharya SM. Prior killing of intracellular bacteria Wolbachia reduces inflammatory reactions and improves antifilarial efficacy of diethylcarbamazine in rodent model of Brugia malayi. Parasitol. Res. 102(5), 963-972 (2008).
245. Mand S, Pfarr K, Sahoo PK et al. Macrofilaricidal activity and amelioration of lymphatic pathology in bancroftian filariasis after 3 weeks of doxycycline followed by single-dose diethylcarbamazine. Am. J. Trop. Med. Hyg. 81(4), 702-711 (2009).
246. Coulibaly YI, Dembele B, Diallo AA et al. A randomized trial of doxycycline for Mansonella perstans infection. N. Engl. J. Med. 361(15), 1448-1458 (2009).
247. Masud H, Qureshi TQ, Dukley M. Effects of Ivermectin with and without doxycycline on clinical symptoms of onchocerciasis. J. Coll. Physicians Surg. Pak. 19(1), 34-38 (2009).
248. Specht S, Mand S, Marfo-Debrekyei Y et al. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitol. Res. 103(6), 1303-1309 (2008).
249. Hoerauf A, Marfo-Debrekyei Y, Büttner M et al. Effects of 6-week azithromycin treatment on the Wolbachia endobacteria of Onchocerca volvulus. Parasitol. Res. 103(2), 279-286 (2008).
250. Supali T, Djuardi Y, Pfarr KM et al. Doxycycline treatment of Brugia malayi infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment. Clin. Infect. Dis. 46(9), 1385-1393 (2008).
251. Debrah AY, Mand S, Marfo-Debrekyei Y, Batsa L, Pfarr K, Buttner M et al. Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti. Trop. Med. Int. Health. 12(12), 1433-1441 (2007).
252. Hoerauf A, Specht S, Büttner M et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med. Microbiol. Immunol. 197(3), 295-311 (2008).
253. Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 365(9477), 2116-2121 (2005).
254. Jolodar A, Fischer P, Butner DW, Brattig NW. Wolbachia endosymbionts of Onchocerca volvulus express a putative periplasmic Htr A-type serine protease. Microbes Infect. 6(2), 141-149 (2004).
255. Bazzocchi C, Ceciliani F, McCall JW et al. Antigenic role of the endosymbionts of filarial nematodes: IgG response against the Wolbachia surface protein in cats infected with Dirofilaria immitis. Proc. R. Soc. Lond. B. Biol. Sci. 267(1461), 2511-2516 (2000).
256. Fischer P, Bonow I, Buttner DW, Kamal IH, Liebau E. An aspartate aminotransferase of Wolbachia endobacteria from Onchocerca volvulus is recognized by IgG1 antibodies from residents of endemic areas. Parasitol. Res. 90(1), 38-47 (2003).
257. Lamb TJ, Le Goff L, Kurniawan A et al. Most of the response elicited against Wolbachia surface protein in filarial nematode infection is due to the infective larval stage. J. Infect. Dis. 189(1), 120-127 (2004).
258. Dangi A, Vedi S, Nag JK et al. Tetracycline treatment targeting Wolbachia affects expression of an array of proteins in Brugia malayi parasite. Proteomics. 9(17), 4192-4208 (2009).
259. Williams SA. Towards a strategic plan for research to support the global program to eliminate lymphatic filariasis. Am. J. Trop. Health Hygiene 71(5 Suppl.), 46 (2004).
260. Oothuman P, Denham DA, Mc Greevy PB, Nelson GS, Rogers R. Successful vaccination of cats against Brugia pahangi with larvae attenuated by irradiation with 10 krad cobalt 60. Parasite. Immunol. 1, 209-216 (1979).
261. Yates JA, Higashi GI. Brugia malayi vaccination of jirds with 60 cobalt attenuated infective stage larvae protects against homologous challenge. Amer. J. Trop. Med. Hyg. 34, 1132-1137 (1985).
262. Chusattayanond W, Denham DA. Attempted vaccination of jirds against Brugia pahangi with radiation attenuated infective larvae. J. Helminthol. 60(2), 149-155 (1986).
263. Abraham D, Grieve RB, Holy JM, Christensen BM. Immunity to larval Brugia malayi in BALB/c mice: protective immunity and inhibition of larval development. Amer. J. Trop. Med. Hyg. 40(6), 598-604 (1989).
264. Bancrofti AJ, Devaney E. The analysis of the humoral response of the BALB/c mouse immunized with radiation attenuated third stage larvae of Brugia pahangi. Parasite Immunol. 15(3), 153-162 (1993).
265. Kazura J, Davis RS. Soluble Brugia malayi microfilarial antigens protect mice against challenge by an antibody dependent mechanism. J. Immunol. 128(4), 1792-1796 (1982).
266. Tanner M, Weiss N. Dipetalonema viteae (Filarioidea): evidence for a serum-dependent cytotoxicity against developing third and fourth stage larvae in vitro. Acta Trop. 38(3), 325-328 (1981).
267. Hayashi Y, Nakagahi K, Nogami S, Harnmerberg B, Tanaka H. Protective immunity against Brugia malayi infective larvae in mice. Parameters of active and passive immunity. Amer. J. Trop. Med. Hyg. 41(6), 650-656 (1989).
268. Lustigman S, MacDonald AJ, Abraham D. CD4+dependent immunity to Onchocerca volvulus third-stage larvae in humans and the mouse vaccination model: common ground and distinctions. Int. J. Parasitol. 33(11), 1161-1171 (2003).
269. Islam MK, Miyoshi T, Yamada M, Tsuji N. Pyrophosphatase of the roundworm Ascaris suum plays an essential role in the worm's malting and development. Infection and Immunity. 73(4), 1995-2004 (2005).
270. Pokharel DR, Rai R ,Kodumudi KN, Reddy MVR, Rathaur S. Vaccination with Setaria cervi 175 kDa collagenase induces high level of protection against Brugia malayi infection in jirds. Vaccine. 24(37-39), 6208-6215 (2006).
271. Hartmann S, Sereda MJ, Sollwedel A, Kalinna B, Lucius R. A nematode allergen elicits protection against challenge infection under specific conditions. Vaccine 24(17), 3581-3590 (2006).
272. Thirugnanam S, Pandiaraja P, Ramaswamy K et al. Brugia malayi: comparison of protective immune responses induced by Bm-alt-2 DNA, recombinant Bm-ALT-2 protein and prime-boost vaccine regimens in a jird model. Exp. Parasitol. 116(4), 483-491 (2007).
273. Vedi S, Dangi A, Hajela K, Misra- Bhattacharya S. Vaccination with 73 kDa recombinant heavy chain myosin generates high level of protection against Brugia malayi challenge in jird and mastomys models. Vaccine 26(47), 5997-6005 (2008).
274. Lafuente LP, Gregory WF, Allen JE, Maizels RM. MIF homologues from a filarial nematode parasite synergize with IL-4 to induce alternative activation of host macrophages. J. Leukoc. Biol. 85(5), 844-854 (2009).
275. Melby PC, Ogden GB, Flores HA et al. Identification of vaccine candidates for experimental visceral leishmanias is by immunization with sequential fractions of a cDNA expression library. Infect. Immunol. 68(10), 5595-5602 (2000).
276. Goyal P, Goyal K, Gurusamy S et al. liposomal drug delivery systems - clinical applications. Acta Pharm. 55(1), 1-25 (2005).
277. Owais M, Bhattacharya SM, Haq W, Gupta CM. Immunomodulator tuftsin augments antifilarial activity of diethylcarbamazine against experimental Brugian filariasis. J. Drug Targ. 11 (4), 247-251 (2003).
278. Bajpai P, Vedi S, Owais M, Sharma SK, Bhattacharya SM. Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in rodent model. J. Drug Target. 13(6), 375-381 (2005).
279. Gavotte L, Henri H, Stouthamer R, Charif D, Charlat S, Boulétreau et al. A Survey of the bacteriophage WO in the endosymbiotic bacteria wolbachia. Mol. Biol. Evol. 24(2), 427-435 (2007).
280. Loiseau PM, Metley Y, Vierford JM. Antifilarial and trypanocidal properties of phenothiazines and related polycyclics as new lead structures. Int. J. Parasitol. 26(10), 1115-1117 (1996).